Erwiderung

Alexander Friedl; Anke Bahrmann

doi:10.1055/a-0827-5987

Diabetologie und Stoffwechsel, Inhaltsverzeichnis

Diabetologie und Stoffwechsel 2019; 14(02): 102-103
DOI: 10.1055/a-0827-5987

Leserbrief

Erwiderung

Alexander Friedl

¹Ärztlicher Leiter Geriatrisches Zentrum Stuttgart, Klinik für Endokrinologie, Diabetologie und Geriatrie, Krankenhaus Bad Cannstatt, Klinikum Stuttgart

,

Anke Bahrmann^*

²Klinik für Kardiologie, Angiologie und Pneumologie, Medizinische Klinik 3, Universitätsklinikum Heidelberg

Literatur
1 Bahrmann A, Bahrmann P, Baumann J. et al. S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabetologie 2018; 13: 423-489
2 Van de Laar FA, Lucassen PL, Akkermans RP. et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 (2):CD003639. DOI: 10.1002/14651858.CD003639.pub2
3 Van de Laar FA, Lucassen PL. α-Glucosidase- Inhibitors for Patients With Type 2 Diabetes. Diabetes Care 2005; 28: 1841
4 Van de Laar FA, Lucassen PL. No evidence for a reduction of myocardial infarctions by acarbose. European Heart Journal 2004; 25: 1179-1180
5 Chen JM, Chang CW, Lin YC. et al. Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study. Cardiovasc Drugs Ther 2017; 31: 401-411
6 Holman RR, Coleman RL, Chan JCN. et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): A randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 877-886
7 Asakura M, Kim J, Asanuma H. et al. Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction?. Cardiovasc Drugs Ther 2017; 31: 401-411
8 Tseng YH, Huang HL, Chu FY. et al. Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study. Diabetes Care 2015; 38: 2068-2074